| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $74.1M | +39.5% |
| SG&A Expense | $31.7M | +105.9% |
| Operating Income | -$105.8M | -54.4% |
| Pre-tax Income | -$98.3M | -48.1% |
| Net Income | -$98.3M | -48.1% |
| EPS (Basic) | -$3.09 | +75.1% |
| EPS (Diluted) | -$3.09 | +75.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $35.0M | -71.2% |
| Short-term Investments | $86.5M | — |
| Current Assets | $126.1M | +1.5% |
| Total Assets | $146.9M | +5.1% |
| Current Liabilities | $22.8M | +32.5% |
| Total Liabilities | $30.1M | +14.6% |
| Stockholders' Equity | $116.8M | +2.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$81.2M | -36.4% |
| Capital Expenditures | $481K | +318.3% |
| Investing Cash Flow | -$94.1M | — |
| Financing Cash Flow | $88.8M | -14.5% |
| Free Cash Flow | -$81.6M | -36.9% |